Q-omics provides the consensus-scored SEC22B profile across patient tissues and cancer cell-line models. SEC22B expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, SEC22B is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, SEC22B RNA expression shows 20,688 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight CESC, THCA, and UVM as cancer lineages where SEC22B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SEC22B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SEC22B survival associations across molecular data types. SEC22B RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SEC22B RNA expression–survival associations across cancer types. High SEC22B expression shows unfavorable associations in CESC, LGG, HNSC, SCLC, LUSC and KIRP. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for SEC22B RNA expression.
This table summarizes SEC22B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SEC22B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SEC22B shows lower tumor expression in THCA and KICH and higher tumor expression in BRCA, LUAD, BLCA and CHOL. The THCA box plot shows higher SEC22B RNA expression in normal versus tumor tissue (log2 FC = −0.775, t-test p < 0.001).
This table shows molecular features associated with SEC22B in patient tissues and cancer cell lines. In patient samples, SEC22B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SEC22B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BONE.
